The Promise and Perils of Diversity Action Plans for Clinical Trials
This Viewpoint discusses the US Food and Drug Administration’s authority to require drug and device sponsors to submit diversity action plans and policy gaps that limit the organization’s ability to achieve demographic representation in clinical trials.
Authors
- Tanvee Varma (ORCID: https://orcid.org/0000-0002-8863-1485)
- Barbara E. Bierer (ORCID: https://orcid.org/0000-0001-6448-8170)
- Andrew Hantel (ORCID: https://orcid.org/0000-0001-9612-3643)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- JAMA
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1001/jama.2024.18225
- Citations
- 1
- Primary Topic
- Health and Medical Research Impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Brigham and Women's Hospital
- Celgene
- Harvard University
- Jazz Pharmaceuticals
- National Institutes of Health
- Genentech
- National Cancer Institute